Alto Neuroscience, Inc.

NYSE:ANRO

Biotechnology

Healthcare
$25.91 +1.84%

+$0.40 today

Market cap
$1.04B
Beta
1.25
P/E (TTM)
-9.8
EPS (TTM)
-$2.26
52W Low $2.15High $28.44

Volume 0.99M

Average 0.34M

Balance Sheet

Inspect the capital base behind the business.

Assets

$184.69M

FY 2025 · Annual

+4.0% YoY

Liabilities

$33.55M

FY 2025 · Annual

+28.6% YoY

Equity

$151.14M

FY 2025 · Annual

-0.2% YoY

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents25.71M48.34M82.55M168.23M176.48M
Short-term Investments00000
Net Receivables1.74M546K8K00
Inventory00000
Other Current Assets002.31M30K1.23M
Total Current Assets27.68M49.22M85.39M169.34M177.72M
Property, Plant & Equipment (Net)1.06M1.58M1.11M7.7M6.13M
Goodwill00000
Intangible Assets00000
Long-term Investments000500K500K
Tax Assets00000
Other Non-current Assets50K55K131K4K338K
Total Non-current Assets1.11M1.63M1.24M8.21M6.97M
Total Assets28.79M50.85M86.63M177.54M184.69M
Account Payables600K1.61M1.07M1.58M1.88M
Short-term Debt0283K00585K
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities1.19M3.54M008.86M
Total Current Liabilities1.81M5.56M5.61M10.01M11.33M
Long-term Debt38.16M81.7M9.86M11.56M3.82M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities1.3M1.88M142.83M018.4M
Total Non-current Liabilities39.46M83.7M152.69M16.07M22.22M
Total Liabilities41.27M89.26M158.3M26.08M33.55M
Common Stock1K1K03K3K
Retained Earnings(12.95M)(40.66M)(76.97M)(138.4M)(201.63M)
Accumulated OCI(22K)(46K)(79K)(101K)22K
Other Stockholders Equity00000
Minority Interest00000
Total Equity(12.48M)(38.41M)(71.67M)151.46M151.14M
Total Debt38.16M82.11M9.99M16.94M4.41M
Net Debt12.46M33.76M(72.56M)(151.29M)(172.08M)

Balance Sheet

Assets, liabilities & equity

Cash & Equivalents$263.8M
Other Current$5.4M
Total Current Assets$269.1M
PP&E (Net)$6.3M
Other Non-current$838.0K
Total Non-current Assets$7.1M
Total Assets$276.3M

Analysis

Selected assets total $276.3M for Latest. The largest visible component is Cash & Equivalents at $263.8M, about 95.5% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 10, 2026
8-KCurrent reportNov 10, 2026
SC 13GSC 13G filingOct 30, 2026
4Statement of changes in beneficial ownershipOct 5, 2026
4Statement of changes in beneficial ownershipOct 1, 2026

How much cash does ANRO have?

Alto Neuroscience, Inc. (ANRO) reported $176.48M in cash and equivalents in fiscal 2025.

How much debt does ANRO carry?

Alto Neuroscience, Inc. (ANRO) reported $4.41M of total debt, with net debt of -$172.08M.